Overview of Ketamine

Property	Description
Active ingredient	Ketamine hydrochloride
Form	Solution for injection, Nasal spray
Pharmacological class	Dissociative Anesthetic, Non-opioid Analgesic
Common use	General anesthesia, Analgesia (pain relief)
Origin	Synthetic compound

What is Ketamine, and What Type of Drug Is It?

Ketamine is a synthetic medicinal compound classified primarily as a Dissociative Anesthetic and a potent Non-opioid Analgesic. The active compound is Ketamine hydrochloride, which exists chemically as a racemic mixture containing two molecular structures, the S- and R-enantiomers. This inherent composition is a key feature that distinguishes it from formulations containing only the S-enantiomer, such as Esketamine.

Ketamine's unique categorization as a dissociative anesthetic stems from its action as a Noncompetitive N-methyl-D-aspartate (NMDA) Receptor Antagonist. This means Ketamine interferes with communication pathways in the central nervous system by blocking the NMDA receptor site. This distinctive mechanism allows the drug to induce a rapid, anesthetic state while promoting cardiorespiratory stability, a property that has been clinically recognized for decades in emergency medicine.

What Is the General Medical Purpose of Ketamine?

The general medical purpose of Ketamine is to provide rapid and effective general anesthesia for medical and surgical procedures and to deliver powerful, fast-acting analgesia (pain relief). Ketamine is indicated for use as an anesthetic agent, either as the sole agent or to induce general anesthesia prior to other agents.

By effectively disrupting the transmission of pain signals through the NMDA receptor pathway, Ketamine's benefit lies in its ability to quickly control severe pain and facilitate necessary medical interventions. A typical use scenario involves its application in trauma care where rapid anesthesia is required but maintaining cardiovascular stability is essential.

What Are the Available Forms of Ketamine?

Ketamine is most commonly supplied as a sterile solution for injection, which allows for parenteral administration, including intravenous (IV) or intramuscular (IM) routes. Other preparations, such as nasal spray formulations, are also utilized in clinical settings. The availability of Ketamine in these various dosage forms provides healthcare professionals with flexible options for prompt administration in diverse clinical environments.

What side effects are possible with Ketamine?

Possible Side Effects and Safety Information

The official safety profile for Ketamine is structured by classifying documented adverse reactions according to frequency and the body system affected, as detailed in regulatory documents such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Adverse Reactions by Frequency

Side effects are categorized based on their rate of occurrence:

Common (reported in 1 to 10 out of 100 people): Includes transient increases in heart rate and blood pressure, nystagmus (involuntary eye movement), nausea, vomiting, and certain psychoactive reactions.
Uncommon (less than 1 in 100 people): Includes decreases in heart rate (bradycardia), low blood pressure (hypotension), and respiratory depression.
Rare (less than 1 in 1,000 people): Includes serious reactions such as anaphylactic reaction, apnoea (cessation of breathing), and hemorrhagic cystitis.

Clinically Significant Safety Considerations

The safety documentation notes the occurrence of emergence reactions, which are transient psychoactive effects (e.g., hallucinations, confusion, and vivid imagery) that typically appear during the recovery period, usually resolving within a few hours.

Specific safety concerns are also noted regarding long-term exposure: Drug-induced liver injury and severe urinary tract disorders, including cystitis, are reported in connection with chronic use.

Population and Condition-Specific Safety Notes:

Official labeling sets constraints for use in patients with pre-existing conditions. It is contraindicated in individuals for whom a significant elevation of blood pressure would constitute a serious hazard, such as those with severe hypertension. Furthermore, regulatory notes indicate that the incidence of emergence reactions is generally lower in older adults. For pediatric patients, animal studies have noted a risk of neurotoxicity when exposure exceeds three hours.

Overdose and Emergency Response

The official literature documents that Ketamine overdosage primarily involves the respiratory, cardiovascular, and central nervous systems. Manifestations include severe respiratory depression, apnea, and a risk of coma or convulsions. Cardiovascular effects, such as an enhanced pressor response (elevated blood pressure), are frequently noted, though severe cases may also involve cardiac compromise. Excessive exposure, such as ten times the required dose or too rapid a rate of administration, has been reported to result in prolonged recovery.

Urgent medical help must be sought immediately for any suspected overdosage, particularly if slowed breathing or loss of consciousness occurs. The regulatory action required for respiratory depression is the mechanical support of respiration, which is preferred over other pharmacological stimulants.

There is no specific antidote known for Ketamine overdose. Management is officially defined as symptomatic and supportive treatment. This includes ensuring a patent airway and continuous monitoring of cardiac function and vital signs in a hospital setting. Cautious use is officially noted for the chronic alcoholic and acutely alcohol-intoxicated patient due to an altered risk profile and potential for prolonged action.

Therapeutic Uses of Ketamine

Ketamine is commonly used across several therapeutic domains, including providing general anesthesia and analgesia (pain relief). In clinical settings, the medication is applied for acute or disruptive symptom patterns and may assist with managing symptoms that create noticeable physiological strain.

Ketamine is commonly used to induce general anesthesia or procedural sedation for medical interventions, manage severe acute pain in trauma, and address refractory chronic pain syndromes. It is also applied in specialized clinical settings to manage critical symptoms of treatment-resistant depression and acute suicidal ideation. This broad use covers conditions where supportive symptom management is appropriate. The primary benefit for patients is that it supports patients during difficult episodes by easing distress when pain or psychiatric symptoms become more noticeable. In situations requiring temporary assistance in symptom stabilization, it helps to maintain cardiovascular stability during anesthesia.

“Ketamine is used in situations involving certain distressing symptoms, contributing to easing the overall symptom load.”

Quick Fact: Relief for Refractory Symptoms Ketamine is relevant for conditions characterized by periods of heightened symptoms, including certain complex pain disorders and severe mood disorders.

Regulatory References

NIH StatPearls overview on Ketamine

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Ketamine (racemic) injection is used as an anesthetic agent and is generally allowed for patients of all ages, provided no specific contraindications or warnings apply. Eligibility is strictly limited by a patient's pre-existing medical conditions.

Eligibility Classification	Affected Population	Status in Regulatory Label
Absolute Contraindication	Patients with known hypersensitivity to ketamine or its excipients.	Contraindicated
Absolute Contraindication	Patients for whom a significant elevation of blood pressure would constitute a serious hazard (e.g., uncontrolled hypertension).	Contraindicated
Conditional Use (Caution)	Patients with pre-anesthetic elevated cerebrospinal fluid pressure (CSFP).	Extreme Caution
Conditional Use (Caution)	Patients with existing hypertension or cardiac decompensation during the procedure.	Continual Monitoring Required
Not Recommended	Pregnant women (safe use is not established) and breastfeeding women.	Not Recommended / Avoid Use
Age-Specific Limitation	Children leq 3 years of age receiving treatment for periods longer than 3 hours.	Neurotoxicity Warning
Age-Specific Limitation	Older adults (Geriatric Use).	Dose adjustment/caution due to decreased organ function

Official regulatory documents define non-eligibility primarily based on the drug's hemodynamic effects, which can dangerously increase blood pressure. Caution is also mandatory for use in specific populations, such as very young children due to potential neurotoxicity and pregnant individuals due to unestablished safety.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ketamine's official interaction profile is characterized by pharmacodynamic and pharmacokinetic patterns documented in regulatory sources, which define specific constraints for co-administration.

Category	Documented Interacting Substances
Pharmacodynamic (PD) Interactions	Opioid Analgesics, Benzodiazepines, Barbiturates, Alcohol (Ethanol), Sympathomimetics, Vasopressin
Pharmacokinetic (PK) Interactions	CYP3A4 Inhibitors (e.g., Grapefruit juice for oral form)
Formal Contraindications	Theophylline, Aminophylline

Official Interaction Statements

Contraindicated Combinations: Co-administration with Theophylline or its derivative Aminophylline is not recommended in some regulatory documents due to the official risk of lowering the seizure threshold.
CNS Depressants: Concomitant use with Opioid Analgesics, Benzodiazepines, Barbiturates, or Alcohol results in a pharmacodynamic interaction leading to additive CNS depression, increasing the potential for profound sedation, respiratory depression, coma, and death. Opioid analgesics may also prolong the time to complete recovery from anesthesia.
Sympathomimetics: Combining Ketamine with Sympathomimetics or Vasopressin may enhance its sympathomimetic effects, resulting in additive increases in blood pressure and heart rate.
Food and Substance Interaction: Grapefruit juice has been shown to significantly increase the systemic exposure (plasma concentrations) of the S-enantiomer of oral ketamine through the inhibition of CYP3A4-mediated metabolism.
Population Note: Caution is specifically noted for use in the chronic alcoholic or acutely alcohol-intoxicated patient due to the enhanced risk of additive CNS depression.

This structure reflects the requirements for close monitoring when combining Ketamine with substances that share an effect profile, and the explicit regulatory restrictions against certain combinations.

Mechanism of Action

Primary Action: Blocking Excitatory NMDA Neurotransmission

Ketamine's core mechanism is its function as a noncompetitive open-channel blocker of the N-methyl- D-aspartate ( NMDA) receptor, an ion channel critical for glutamate-mediated excitatory signaling. By physically obstructing this ion channel in key brain circuits, the drug functionally decouples thalamoneocortical activity, which mediates sensory integration and higher- order cortical functions, leading to an interruption of nociceptive signal processing. This interference with excitatory transmission also disrupts the establishment of hyperexcitability in spinal nociceptive neurons.

Downstream AMPA Activation and Neuroplasticity

Beyond the initial NMDA blockade, Ketamine also modulates other signaling pathways. The NMDA antagonism preferentially occurs on inhibitory GABAergic interneurons, leading to the disinhibition of pyramidal neurons and a temporary glutamate surge. This surge activates AMPA receptors downstream, initiating signaling cascades involving mTOR and BDNF production that support synaptic remodeling.

Sympathetic System Modulation and Multi-Target Effects

Ketamine's overall physiological effect is shaped by secondary, lower-affinity interactions, including the inhibition of norepinephrine reuptake and serotonin reuptake, which drives sympathetic nervous system stimulation. This stimulation results in increased heart rate and elevated peripheral vascular tone. Furthermore, the drug’s racemic composition means its S- and R-enantiomers contribute differently to the overall NMDA antagonism and neuroplastic modulation.

Dosage and Administration Information

Ketamine administration is determined by its specific dosage form, which includes the racemic solution for injection and the S-enantiomer, Esketamine nasal spray. The solution is administered via Intravenous (IV) or Intramuscular (IM) routes for anesthesia and sedation. The IV induction dose typically ranges from 1 mg/kg to 4.5 mg/kg and must be delivered slowly over a period of 60 seconds. Anesthesia maintenance is achieved through repeat doses, or by continuous IV infusion. Special care is required for preparation; the highest 100 mg/mL concentration of the solution must be diluted with an equal volume of a diluent prior to intravenous use.

The Esketamine nasal spray is strictly for the Intranasal route and requires a defined, time-structured schedule. Treatment initiates with an Induction Phase of 56 mg or 84 mg administered twice per week for the first four weeks. This transitions to a Maintenance Phase, where the administration frequency is reduced to once weekly or every two weeks. For this specific form, patients are instructed to avoid food for at least 2 hours and liquids for at least 30 minutes before administration. All usage of both forms must occur under direct supervision in a specialized healthcare setting. Dosage for older adults requires caution and typically utilizes the lower end of the established range. This highly structured usage protocol ensures adherence to the specific frequency, dose, and environmental constraints.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ketamine

Evidence for Use in General Anesthesia and Procedural Sedation

Ketamine was evaluated in research exploring its profile as an anesthetic agent. This research involves comprehensive analyses of its use during medical and surgical procedures, including observational studies and clinical trials that span decades. The studies primarily monitored outcomes related to the depth of the anesthetic state, how quickly the patient emerged from the state, and also outcomes monitoring physiological strain or stress, such as heart rate and blood pressure stability.

Evidence for Use in Acute Pain Management

Research was studied for Ketamine in acute pain management, such as post-operative pain or pain from trauma. These studies often involved short-term Randomized Controlled Trials (RCTs) which examined outcomes related to physical discomfort using pain scales. They also monitored measurements related to concurrent use of opioid pain medications among the study participants. Findings across different trials described patterns observed in the studies related to measured changes in pain intensity scores in the hours and days immediately following administration.

Evidence for Use in Treatment-Resistant Depression and Acute Suicidal Ideation

For conditions characterized by fluctuating or episodic manifestations like treatment-resistant depression, research mainly involves short-term clinical trials and meta-analyses. These studies examined outcomes related to systemic or functional imbalance using specific rating scales that measure changes in symptoms of depression. Research for this use describes patterns related to rapid changes in depression severity scores, often within hours of administration.

What is Still Uncertain About the Research

Current research highlights that a number of questions remain open. Evidence quality varies across studies, particularly for chronic pain and some uses in mental health. Follow-up durations were limited in many key trials, meaning long-term effects are not fully established and there is limited information for long-term outcomes. This evidence highlights what is known — and what is still uncertain about which specific groups or conditions associated with acute or disruptive episodes may be relevant for further study. Comparative evidence is lacking in some areas, meaning direct trial-to-trial comparisons with other existing treatments are sometimes limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ketamine (FAQ)

Q: How quickly does Ketamine start working for its medical purposes?

According to official product information, the onset of the anesthetic effect depends on the route of administration. An intravenous dose typically produces surgical anesthesia within 30 seconds. An intramuscular dose usually achieves this state within 3 to 4 minutes following injection.

Q: What is the expected length of time that the effects of Ketamine last?

Regulatory documents describe the typical duration of the anesthetic effect based on how the medicine is given. The effect usually lasts 5 to 10 minutes following an intravenous dose. For an intramuscular dose, the anesthetic state generally lasts longer, between 12 to 25 minutes.

Q: What is the difference between Ketamine and general anesthesia?

Ketamine is specifically classified as a Dissociative Anesthetic, which means it induces an anesthetic state that is distinct from conventional general anesthesia. Its primary action is blocking the NMDA receptor, which interferes with communication in key brain circuits. This unique mechanism is what gives Ketamine its classification.

Q: Does Ketamine cause drowsiness or fatigue?

The official safety profile notes that drowsiness and confusion are possible effects associated with its use. These feelings are often part of the transient psychoactive reactions, sometimes referred to as 'emergence reactions,' that may occur during the recovery period.

Q: Are there any major interactions between Ketamine and anxiety medications?

Regulatory warnings specifically address the use of Ketamine with Benzodiazepines, which are a class of medications used for anxiety. Concomitant use with these substances results in an additive central nervous system (CNS) depressant effect. This interaction can increase the risk of profound sedation and respiratory depression.

Q: Is Ketamine a controlled substance in the US or other countries? / What is the scheduling of Ketamine (Schedule III, etc.)?

Official government agencies, such as the U.S. Drug Enforcement Administration, classify Ketamine as a Schedule III non-narcotic controlled substance. This classification indicates that the drug has an accepted medical use but also carries a potential for abuse and physical or psychological dependence.

Q: Is there a risk of becoming dependent on Ketamine if used medically?

Official labeling and legal classifications recognize Ketamine as having a potential for abuse and misuse. Due to this risk, the drug is a controlled substance with a potential for both psychological and physical dependence.

Q: Are there certain foods or supplements to avoid when receiving Ketamine?

Official regulatory instructions advise avoiding food for at least two hours and liquids for at least 30 minutes before administration of the nasal spray formulation. Official drug interaction information also notes that Grapefruit juice is to be avoided because it can significantly increase the drug's blood levels.

Q: What are the general guidelines for someone who has received Ketamine for a procedure?

Official post-procedure guidance states that the patient should be accompanied by an adult to go home after the procedure. Activities like driving, operating hazardous equipment, or making important decisions are to be avoided for the remainder of the day, as these precautions are recommended until the drug's effects have fully worn off.

Q: Can I drive or operate machinery after receiving Ketamine for a medical reason?

Regulatory warnings describe that driving, operating hazardous equipment, or performing hazardous activities are to be avoided for the rest of the day following administration. These restrictions are in place until the effects of the medicine have completely subsided.

Q: Can Ketamine be used in patients with pre-existing kidney issues?

Official drug labeling notes that caution is generally advised for patients with pre-existing kidney disease. Official labeling states that monitoring of renal function is a clinical consideration, particularly during long-term use.

Q: Does Ketamine cause changes in appetite?

The official safety documentation lists loss of appetite (anorexia) as a common gastrointestinal adverse reaction. This is one of the possible effects patients may experience after administration.

Q: What happens if a person misses a planned Ketamine treatment session?

General protocol documented by medical authorities indicates that a missed dose is typically taken as soon as remembered, unless it is close to the next scheduled dose. Official guidance specifies that doubling a dose to compensate is to be avoided.

Q: Is Ketamine used in veterinary medicine?

Ketamine is medically approved for use in both humans and animals. In both contexts, it serves as a general anesthetic and sedative agent for short-term procedures.

Q: Do the side effects of Ketamine change based on the route of administration?

Pharmacokinetic data suggests that the route of administration (such as intravenous versus intramuscular) influences the drug's absorption and distribution. These differences in how the body handles the drug can, in turn, affect the onset, duration, and the patient's experience of associated side effects.

Q: Can Ketamine interact with herbal supplements like St. John's Wort?

Official product information classifies the coadministration of Ketamine with St. John's Wort as requiring close monitoring. This is due to the potential for increased side effects such as excessive sedation, dizziness, and respiratory depression.

Q: Can patients with a history of substance use disorder receive Ketamine?

Ketamine is a controlled substance with a known potential for abuse and misuse. Official regulatory documents emphasize the importance of a thorough medical assessment when considering use in any patient.

Q: Is there a patient registry for people receiving Ketamine for certain treatments?

While there may not be a single national registry, official databases like the EU Clinical Trials Register (EudraCT) and ClinicalTrials.gov document the numerous studies and trials involving Ketamine. These regulatory tools track research into various potential uses.

Q: What should a patient do if they feel unusual effects after leaving the medical facility?

Regulatory guidance advises that medical attention is to be sought if a patient experiences unusual effects, especially signs of serious adverse reactions like right upper belly pain, fever, dark urine, or yellowing skin or eyes.

Q: What is the duration of Ketamine's presence in the body after administration?

Pharmacokinetics data from regulatory sources provide details on how long the substance remains in the body. Ketamine is eliminated in phases, with the terminal elimination half-life of 5.2 to 6.1 hours.

How should Ketamine be stored and disposed of?

How to Store and Dispose of Ketamine

Ketamine injection must be stored strictly according to official regulatory labeling to ensure product integrity and safety.

Storage Requirements

Ketamine must be stored at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F), and must not be frozen. The product must be protected from light and kept in its original container.

For child safety, the medicine must be stored out of the sight and reach of children.

Stability and Handling

Any diluted solutions must be used immediately or within the specified stability window and any unused portion discarded. Multi-dose vials may require discarding 28 days after initial use. The solution must be visually inspected and discarded if discolored or containing particulate matter.

Disposal

As a Controlled Substance, disposal of unused or expired Ketamine must adhere to local, regional, and national regulations. It should not be disposed of via household waste or wastewater unless specifically instructed by regulatory guidelines, and should instead be returned through an approved take-back program.

Ketamine